Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Recruiting

Phase 1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaIntralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Sponsor:

Carlo Contreras

Code:

NCT04697576

Conditions

Clinical Stage I Cutaneous Melanoma AJCC V8

Clinical Stage IA Cutaneous Melanoma AJCC V8

Clinical Stage IB Cutaneous Melanoma AJCC V8

Clinical Stage II Cutaneous Melanoma AJCC V8

Clinical Stage IIA Cutaneous Melanoma AJCC V8

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ipilimumab

Nivolumab

Pembrolizumab

Quadrivalent Inactivated Influenza Vaccine

Resection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-30. This information was provided to ClinicalTrials.gov by Carlo Contreras on 2024-10-08.